利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.023 秒)

    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    7.
    发明授权
    COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 有权
    作为蛋白激酶抑制剂的化合物和组合物

    公开(公告)号：EP2027123B1

    公开(公告)日：2011-02-23

    申请号：EP07797441.8

    申请日：2007-05-11

    申请人： IRM LLC

    发明人： REN, Pingda ,  WU, Baogen ,  ZHANG, Guobao ,  XIE, Yongping ,  OKRAM, Barun ,  NIKULIN, Victor ,  WANG, Xia ,  CHOI, Ha-soon

    IPC分类号： C07D471/14 ,  A61K31/4375

    CPC分类号： C07D471/14

    摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Bcr-Abl(T315I), ALK5BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-IR, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

    摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及AbI，Bcr-Abl异常活化的疾病或病症的方法 ，Bcr-Abl（T315I），ALK5BLK，BMX，BRK，C-kit，c-RAF，CSK，c-SRC，EGFR，Fes，FGFR3，Flt3，Fms，Fyn，IGF-IR，IR， ，JAK（3），KDR，Lck，NLK，p70S6K，PDGFRα，Ros，SAPK2α，SGK，SIK，Syk，Tie2和TrkB激酶。

    PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF
    8.
    发明公开
    PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF 审中-公开
    蛋白激酶抑制剂及其使用方法

    公开(公告)号：EP2170867A1

    公开(公告)日：2010-04-07

    申请号：EP08770592.7

    申请日：2008-06-10

    申请人： IRM LLC

    发明人： HUANG, Shenlin ,  LIU, Zuosheng ,  ALBAUGH, Pamela, A. ,  WANG, Xing ,  PAN, Shifeng ,  XIE, Yongping ,  ZHANG, Guobao

    IPC分类号： C07D401/14 ,  C07D403/04

    CPC分类号： C07D401/14 ,  C07D403/04

    摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, SAPK2α, Src, SIK, Syk, Tie2 and TrkB kinases.